Putting Patients First Blog

SEPTEMBER 20, 2024

NHC Provides Input on Patient Engagement in Medicare Drug Price Negotiations September 20, 2024 By: Allen Pinn, Coordinator, Policy August 16 marked two years since the Inflation Reduction Act (IRA) was signed into law. Earlier this year CMS released draft guidance for Initial Payment Applicability Year (IPAY) 2027.

Drug Pricing 52

Drug Pricing Communication Vaccines 52

STAT

DECEMBER 28, 2023

STAT’s taking a look at some of the recent health policy trends that states will start to implement in 2024. For most states, the new year means a new legislative session.

Drug Pricing 282

Drug Pricing Hospitals 282

Drug Channels

JANUARY 3, 2024

It's time for Drug Channels ’ annual reality check on U.S. drug pricing. For 2023, brand-name drugs’ list prices again grew at mid-single-digit rates. However, net prices dropped for an unprecedented sixth consecutive year. Details below.

Drug Pricing 74

Drug Pricing 74

Safe Biologics

FEBRUARY 1, 2024

Comments may be submitted here until April 30, 2024. UPCOMING EVENTS WHO 78th INN Consultation Geneva, Switzerland – March 19, 2024 ASCO Annual Meeting Chicago, IL – May 31-June 4, 2024 BIO International Meeting San Diego, CA – June 3-6, 2024 DIA Global Annual Meeting San Diego, CA – June 16-20, 2024

Biosimilars 130

Biosimilars Documentation Drug Pricing 130

Drug Channels

MAY 21, 2024

Fein, president of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for DCI’s new live video webinar: The 340B Drug Pricing Program: Trends, Controversies, and Outlook This event will be broadcast live on Friday, June 21, 2024, from 12:00 p.m. to 1:30 p.m. All rights reserved.

Drug Pricing 52

Drug Pricing 52

BioPharma Dive

JANUARY 10, 2024

In the background, a contentious drug pricing law looms. Many drugmakers hope to compete in obesity, while others seek to win oncology’s next era.

Drug Pricing 120

Drug Pricing 120

STAT

MARCH 18, 2024

The biggest enticement that large pharmacy benefit managers offer to the employers that hire them is drug rebates — a steady stream of money sent back to their clients, a tangible symbol of the discounts that PBMs are able to wrangle out of pharmaceutical companies. Continue to STAT+ to read the full story…

Biosimilars 363

Biosimilars Drug Pricing Documentation Pharmaceutical Companies 363

Pharmaceutical Technology

FEBRUARY 15, 2024

In 2023, Japan approved the outlines of its drug pricing and repricing reform for NHI-listed drugs that will take effect in FY 2024 and FY 2025.

Drug Pricing 52

Drug Pricing 52

pharmaphorum

JANUARY 10, 2024

Policy strategists, like the experts at Avalere, are essential in navigating the seismic policy changes expected in 2024. This includes areas such as drug pricing and patient access. Learn more about their insights and recommendations for the future.

Drug Pricing 52

Drug Pricing 52

Drug Channels

MARCH 19, 2024

I am pleased to announce our new 2024 Economic Report on U.S. Download a free report overview (including key industry trends, the Table of Contents, and a List of Exhibits) HMP Global’s Drug Channels Institute releases ‘2024 Economic Report on U.S. The 2024 Economic Report on U.S. Read on for some additional details.

Drug Pricing 71

Drug Pricing 71

Drug Channels

MARCH 7, 2024

On March 19, 2024, Drug Channels Institute will release The 2024 Economic Report on U.S. drug pricing, reimbursement, and dispensing system. prescription drug channels. prescription drug channels. Review pricing/license options and place a preorder. Pharmacies and Pharmacy Benefit Managers.

Drug Pricing 78

Drug Pricing 78

Drug Channels

OCTOBER 2, 2024

This week, I’m rerunning some popular posts while we put the finishing touches on DCI’s new 2024-25 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. Click here to see the original post from June 2024. Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company.

Hospitals 52

Hospitals Specialty Pharmacies Drug Pricing 52

PharmExec

MAY 21, 2024

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Drug Pricing 52

Drug Pricing 52

Drug Channels

DECEMBER 5, 2023

The common factor behind these two disparate situations: Pharmaceutical wholesalers’ unusual pricing for brand-name drugs sold to pharmacies, hospitals, and other buyers. Below, I walk through the economic fundamentals to help you understand another obscure aspect of our opaque drug pricing system. to 1:30 p.m.

Drug Pricing 83

Drug Pricing Hospitals 83

pharmaphorum

APRIL 13, 2022

Unfortunately, the current drug pricing bill fails to take a holistic approach to addressing a system that drives affordability challenges for patients. The non-profit drugmaker plans to launch biosimilars of Sanofi’s Lantus (insulin glargine), Novo Nordisk’s Novolog (insulin aspart) and Eli Lilly’s Humalog (insulin lispro) by 2024.

Drug Pricing 130

Drug Pricing Diabetes Biosimilars 130

Pharmaceutical Technology

SEPTEMBER 17, 2024

The company claims that the FTC’s July 2024 report is riddled with “false and misleading claims” about the PBM industry.

Drug Pricing 52

Drug Pricing 52

STAT

FEBRUARY 15, 2024

The pharmaceutical industry, in court and in Congress, is working to water down legislation that will let Medicare negotiate certain drug prices. STAT Washington correspondent Rachel Cohrs joins us to explain the industry’s struggle to make headway — and how it factors into the 2024 election.

Drug Pricing 257

Drug Pricing 257

Drug Channels

NOVEMBER 14, 2023

Fein, CEO of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for DCI’s new live video webinar: Drug Channels Outlook 2024 This event will be broadcast live on Friday, December 15, 2023 12:00 p.m. This event is part of The Drug Channels 2023 Video Webinar Series. Dr. Adam J.

Drug Pricing 76

Drug Pricing Biosimilars 76

Definitive Healthcare

FEBRUARY 23, 2024

Resource Type E-Books & How-To Guides Blog How-To Guide Healthcare Insight Medical claims 101: What you need to know How to sell effectively to healthcare facilities and executives using the right… Hospital payor mix by state Image Image Image ","nextArrow":" ","appendArrows":".coh-slider-nav-bottom","dots":false,"draggable":true,"swipe":true,"fade":false,"vertical":false,"speed":700,"cssEase":"ease","pauseOnHover":false,"pauseOnDotsHover":false,"autoplay":false,"rows":0},"sm":{"slidesToShow":2,

Drug Pricing 52

Drug Pricing Hospitals Drug Development 52

STAT

AUGUST 10, 2023

By doing so, the company would sell more medicines in the window before Medicare is allowed to negotiate prices, because the clock for when discounts can kick in is based on when the drug first goes on the market. Novo Nordisk will continue to restrict U.S. demand , STAT notes. The

Drug Pricing 245

Drug Pricing Diabetes 245

Pharmaceutical Commerce

OCTOBER 16, 2024

The session dives into the obstacles surrounding data usability, mandate compliance, initial adoption, and limitations in this arena.

Drug Pricing 52

Drug Pricing 52

Drug Channels

JULY 12, 2024

Gavin discusses the three key reasons for duplicate discounts between the 340B Drug Pricing Program and the Medicaid Drug Rebate Program. To learn more, register for Kalderos’ August 21, 2024, webinar: Revolutionizing Government Discount Programs: Why Traditional Methods Fail. Read on for Gavin’s insights.

Drug Pricing 94

Drug Pricing 94

Drug Channels

JUNE 12, 2024

Drug Channels Institute’s exclusive analysis of the 2024 market reveals that: About 33,000 pharmacy locations—more than half of the entire U.S. on June 21 for his latest live video webinar: The 340B Drug Pricing Program: Trends, Controversies, and Outlook. Fein, Ph.D., All rights reserved.

Hospitals 52

Hospitals Specialty Pharmacies Drug Pricing 52

STAT

FEBRUARY 1, 2024

On 2024 guidance, Merck said it expects sales in the range of $62.7-$64.2 Biotech can’t shake the Fed The XBI, a closely watched index of biotech stocks, turned red for the year yesterday, and not because of a clinical disappointment, a drug pricing scandal, or an M&A rumor that came to nothing.

Drug Pricing 304

Drug Pricing Vaccines Communication Drug Development 304

STAT

OCTOBER 1, 2022

Amylyx did not immediately disclose how much it will charge for Relyvrio, but the company is conducting a larger, longer clinical trial to confirm the benefits, with data expected in late 2023 or early 2024. In a rare commitment, the company has promised to remove the drug from the market if that study is not successful.

Drug Pricing 246

Drug Pricing 246

Drug Channels

OCTOBER 22, 2024

Reality has again failed to support the spin surrounding the 340B Drug Pricing Program. The gross-to-net difference between list prices and discounted 340B purchases also grew, to $57.8 340B purchases are now almost 40% larger than Medicaid’s prescription drug purchases. billion—an astounding $12.6 billion (+$5.5

Drug Pricing 81

Drug Pricing Hospitals 81

Big Molecule Watch

JULY 18, 2023

On June 30, 2023, the Centers for Medicare & Medicaid Services (CMS) released its updated final program guidance covering the Inflation Reduction Act’s Medicare Drug Price Negotiation Program for the first round of negotiations, which will occur during 2023 and 2024 and result in prices that will be effective beginning in 2026.

Drug Pricing 52

Drug Pricing 52

Drug Channels

MAY 29, 2024

Register now for The 340B Drug Pricing Program: Trends, Controversies, and Outlook , a new live video webinar with Adam J. Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. Join my nearly 56,000 LinkedIn followers for daily links to neat stuff. All rights reserved.

Biosimilars 52

Biosimilars Drug Pricing 52

STAT

DECEMBER 27, 2023

As another year comes to an end and the world seems to hit the proverbial pause button, the temptation to look ahead is too great to ignore. After all, this is what journalists like to do as the calendar turns another page. So once again, we will take a whack at identifying some of the most noteworthy developments to watch.

Drug Pricing 280

Drug Pricing 280

STAT

OCTOBER 18, 2024

As Election Day 2024 gets closer, STAT’s First Opinion asked executives from leading biotech and pharmaceutical companies to reflect on how their industry is being portrayed in the presidential campaign — and what their hopes are for a new presidential administration. You

Pharmaceutical Companies 261

Pharmaceutical Companies Pharmaceutical Companies Drug Pricing 261

Putting Patients First Blog

SEPTEMBER 11, 2023

NHC comments on the 2024 Physician Fee Schedule September 11, 2023 By: Allen Pinn, Coordinator, Policy On July 13, the Centers for Medicare & Medicaid Services (CMS) released their proposed rule for the 2024 Physician Fee Schedule. Below is a summary of the NHC’s comments submitted September 11, 2023.

Drug Pricing 59

Drug Pricing 59

Drug Channels

MARCH 12, 2024

Next week, Drug Channels Institute (DCI) will release our 2024 Economic Report on U.S. drug pricing, reimbursement, and dispensing system. We’re offering special discounted pricing if you order before April 7, 2024. Pharmacies and Pharmacy Benefit Managers. For 2023, DCI estimates that U.S. to 1:30 p.m.

Drug Pricing 80

Drug Pricing 80

STAT

JANUARY 11, 2024

JPM Week is finally drawing to a close, sending the drug industry’s many financiers scattering from San Francisco to their respective homes and ski destinations. In honor of JPM Week, you’re reading a special edition of our biotech newsletter, The Readout.

Drug Pricing 267

Drug Pricing Drug Development 267

Digital Pharmacist

APRIL 25, 2023

f you’re an independent pharmacy owner or pharmacist, you’re probably aware of the upcoming changes to DIR fees that will take effect in 2024. In this blog post, we will discuss the evolution of DIR fees leading up to the DIR fee changes coming in 2024, and the pros and cons independent pharmacies owners should prepare for.

Independent Pharmacies 98

Independent Pharmacies Drug Utilization Review Drug Pricing Pharmacy Management 98

Pharma in Brief

SEPTEMBER 28, 2023

As explained in greater detail below, consultation on replacement guidelines is now expected to take place in 2024. The Amendments As we reported , the original Interim Guidance did not contemplate price review for New Medicines during the Interim Period.

Drug Pricing 52

Drug Pricing 52

Big Molecule Watch

NOVEMBER 6, 2023

The licensure and marketing of WEZLANA could affect negotiations with CMS regarding Medicare pricing for STELARA under the Inflation Reduction Act’s Drug Price Negotiation Program. For drugs selected for the first year of the Program, negotiations will end by August 1, 2024.

Drug Pricing 67

Drug Pricing Biosimilars 67

Drug Channels

FEBRUARY 7, 2024

And contrary to what you might read, drug spending growth was *not* driven by purportedly “skyrocketing” drug prices. In reality, nearly all drug spending growth occurred due to growth in the number of people treated, prescriptions dispensed, and other nonprice factors. healthcare expenditures. healthcare expenditures.

Drug Pricing 92

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies 92